AdventHealth and Anthem Blue Cross Blue Shield of Georgia Ink Multi-Year Deal to Broaden Access to Quality Care in Northwest Georgia

AdventHealth and Anthem Blue Cross Blue Shield of Georgia Ink Multi-Year Deal to Broaden Access to Quality Care in Northwest Georgia

AdventHealth and Anthem Blue Cross Blue Shield of Georgia Ink Multi-Year Deal to Broaden Access to Quality Care in Northwest Georgia AdventHealth and Anthem Blue Cross Blue Shield of Georgia (Anthem) are pleased to announce a new multi-year contractual agreement…

Read MoreAdventHealth and Anthem Blue Cross Blue Shield of Georgia Ink Multi-Year Deal to Broaden Access to Quality Care in Northwest Georgia
HistoSonics Secures Expanded Insurance Coverage for Liver Tumor Therapy, Reaching 7 Million Highmark Blue Cross Blue Shield Members

HistoSonics Secures Expanded Insurance Coverage for Liver Tumor Therapy, Reaching 7 Million Highmark Blue Cross Blue Shield Members

HistoSonics , maker of the Edison® Tissue Ablation System , today announced that Highmark Blue Cross Blue Shield has issued four new positive medical policy decisions for the use of Tissue Ablation technology in the treatment of liver tumors. The decisions expand…

Read MoreHistoSonics Secures Expanded Insurance Coverage for Liver Tumor Therapy, Reaching 7 Million Highmark Blue Cross Blue Shield Members
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Process for Personalized RNA Cancer Therapies

Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Process for Personalized RNA Cancer Therapies

Elegen , a leading next-generation DNA manufacturer, and Nutcracker Therapeutics , a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics…

Read MoreElegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Process for Personalized RNA Cancer Therapies
CEL-SCI to Partner With Leading Saudi Pharma Firm to Advance Multikine for Head and Neck Cancer Treatment

CEL-SCI to Partner With Leading Saudi Pharma Firm to Advance Multikine for Head and Neck Cancer Treatment

CEL-SCI to Partner With Leading Saudi Pharma Firm to Advance Multikine for Head and Neck Cancer Treatment Today announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical and healthcare companies for a partnership that spans regulatory…

Read MoreCEL-SCI to Partner With Leading Saudi Pharma Firm to Advance Multikine for Head and Neck Cancer Treatment
Elegen and Nutcracker Therapeutics Launch Pilot of First Fully Cell-Free Manufacturing Process for Personalized RNA Cancer Therapies

Elegen and Nutcracker Therapeutics Launch Pilot of First Fully Cell-Free Manufacturing Process for Personalized RNA Cancer Therapies

A global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer…

Read MoreElegen and Nutcracker Therapeutics Launch Pilot of First Fully Cell-Free Manufacturing Process for Personalized RNA Cancer Therapies
Parse Technology-Powered Research Maps Neuronal Pathways, Advancing Neurodegenerative Disease Insights

Parse Technology-Powered Research Maps Neuronal Pathways, Advancing Neurodegenerative Disease Insights

Parse Biosciences, a leading provider of easy-to-use and scalable single-cell sequencing solutions, today announced that a groundbreaking study published in Science used Parse’s single-cell technology to reveal how signaling pathways drive the formation of multiple neuronal subtypes. By linking specific signals to cell fate…

Read MoreParse Technology-Powered Research Maps Neuronal Pathways, Advancing Neurodegenerative Disease Insights
Clinics

Artificial Intelligence in Clinics Set to Transform Diagnostic Practices – ResearchAndMarkets.com

Artificial Intelligence in Clinics Set to Transform Diagnostic Practices – ResearchAndMarkets.com Smart In-Vitro Diagnostics Market Report Highlights the Growing Role of AI in Healthcare New report from ResearchAndMarkets.com explores how artificial intelligence is transforming the in-vitro diagnostics (IVD) industry. A…

Read MoreArtificial Intelligence in Clinics Set to Transform Diagnostic Practices – ResearchAndMarkets.com
iFIT Teams Up with Samsung Health to Offer Personalized Fitness and Wellness Experiences Globally

iFIT Teams Up with Samsung Health to Offer Personalized Fitness and Wellness Experiences Globally

iFIT Teams Up with Samsung Health to Offer Personalized Fitness and Wellness Experiences Globally iFIT, a global leader in connected fitness devices and interactive content, today announced a groundbreaking partnership with Samsung Health, one of the most trusted names in…

Read MoreiFIT Teams Up with Samsung Health to Offer Personalized Fitness and Wellness Experiences Globally
Personalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer

Personalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer

Personalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer Today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization…

Read MorePersonalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer
CyPath® Lung Identifies Stage 1A Lung Cancer in High-Risk Patient Despite Inconclusive Imaging

CyPath® Lung Identifies Stage 1A Lung Cancer in High-Risk Patient Despite Inconclusive Imaging

BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company addressingthe need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma lung cancer in…

Read MoreCyPath® Lung Identifies Stage 1A Lung Cancer in High-Risk Patient Despite Inconclusive Imaging
Exact Sciences Secures Medicare Coverage for Oncodetect™ MRD Test in Colorectal Cancer

Exact Sciences Secures Medicare Coverage for Oncodetect™ MRD Test in Colorectal Cancer

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services…

Read MoreExact Sciences Secures Medicare Coverage for Oncodetect™ MRD Test in Colorectal Cancer